The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Apixaban as Treatment of Venous Thrombosis in Patients With Cancer: The CAP Study
Official Title: Apixaban as Treatment of Venous Thrombosis in Patients With Cancer: The CAP Study
Study ID: NCT02581176
Brief Summary: This study is a single-arm, phase IV trial, of apixaban as treatment of venous thrombosis in patients with cancer. The current standard treatment of venous thrombosis in cancer patients is subcutaneous injections with low molecular weight heparin. During the last 5 years several new direct acting oral anticoagulants have been tested out as treatment of venous thrombosis. But very few cancer patients were included in the phase III clinical trials of the direct acting oral anticoagulants. Thus, there is a lack of information on how cancer patients with venous thrombosis will respond to treatment with direct acting oral anticoagulants. The current study will investigate the direct acting oral anticoagulant apixaban in cancer patients with venous thrombosis.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Haukeland University Hospital, Bergen, , Norway
Vestre Viken- Drammen Hospital, Drammen, , Norway
Vestre Viken - Bærum sykehus, Gjettum, , Norway
Department of Hematology, Akershus University Hospital, Lørenskog, , Norway
Oslo University Hospital, Oslo, , Norway
Østfold Hospital Kalnes, Sarpsborg, , Norway
Stavanger University Hospital, Stavanger, , Norway
St. Olavs Hospital, Trondheim, , Norway
Volda Hospital, Volda, , Norway
Name: Anders EA Dahm, MD, PhD
Affiliation: University Hospital, Akershus
Role: PRINCIPAL_INVESTIGATOR